RE:RE:RE:New ArticleAnother good article here at Midas Letter on this transaction. I would add that it is in the best interests of the large share holders at Medrelief to keep the ACB share price propped up until the deal closes. The top 4 or 5 holders own something like $1.7 billion shares of Leaf. For example buying even 20-30 million shares on an ongoing basis for this purpose would be very beneficial when their shares get converted at 3.575 rates. However, if there was enough share holder sell off whereas the deal still goes through but ACB decrements, then existing Leaf shareholders would benefit less and the public investors of ACB would have to burden less of the dilution. Keep an eye on the closing date...
https://midasletter.com/2018/05/market-not-fully-buying-into-aurora-cannabis-medreleaf-acquisition-yet/